BCL2 and neoplasm: In AML leukemic stem cells (LSCs) characterized by a low ROS content and a high Bcl-2 expression, venetoclax inhibits oxidative phosphorylation, resulting in the selective eradication of this tumor-promoting cell population, which might contribute to the meaningful activity of venetoclax observed in AML clinical trials [11,12].